Rocket Medical Plc has introduced the HyView HSG and HyCoSy Catheter, a new medical device designed for use in hysterosalpingography (HSG) and Hysterosalpingo Contrast Sonography (HyCoSy), two imaging procedures commonly utilized in the evaluation of female infertility. This innovative catheter aims to improve the effectiveness and reliability of these diagnostic procedures, which are crucial for understanding reproductive health.
Enhancing Fertility Diagnostics with Lipiodol
HSG and HyCoSy procedures involve the introduction of an imaging medium through a catheter to assess the shape of the uterus and the patency of the fallopian tubes. This is done in real-time using fluoroscopy for HSG or ultrasound for HyCoSy. While water-based media is typically used, Lipiodol® Ultra Fluid, an oil-based contrast agent, has been shown to have additional benefits.
Research indicates that Lipiodol used in HSG may increase pregnancy and live birth rates compared to water-based contrast mediums. Additionally, studies suggest that Lipiodol may offer particular benefits for women with endometriosis, with one New Zealand randomized trial showing improved fertility outcomes for up to six months following a Lipiodol flush. The benefits may be more pronounced in women with unexplained infertility.
Overcoming Limitations in Catheter Durability
Despite the promising findings regarding Lipiodol’s role in fertility treatments, one challenge has been the limited availability of suitable catheters that can withstand the oil-based contrast without degradation. Many existing catheters suffer damage after brief exposure to Lipiodol, making them unsuitable for extended use.
The HyView catheter has undergone extensive testing for durability and reliability, particularly with Lipiodol. This catheter has been proven to maintain its integrity for up to 60 minutes, allowing clinicians to perform the procedure effectively, even in more complex cases. This advancement ensures that healthcare providers can rely on the device for longer durations, improving the quality and consistency of diagnostic imaging.
Supporting Clinicians and Expanding Market Reach
Daniel J. Agustus, PhD., Managing Director at Rocket Medical, emphasized the critical role of Lipiodol HSG in fertility management, noting that the HyView catheter is an essential addition to their existing portfolio. The device is designed to meet the evolving needs of clinicians, providing a Lipiodol-resistant solution that enhances the diagnostic process for infertility patients.
Currently, the HyView catheter is available in the UK, Ireland, the Netherlands, Australia, and New Zealand, with plans for further expansion into additional markets. The catheter is offered in two variations: 5FG without a stylet and 5FG with a stylet, the latter being particularly helpful for difficult insertions.
This new device marks a significant step forward in the field of fertility diagnostics, offering clinicians a reliable, durable tool to improve patient outcomes in infertility investigations and treatments.
Related topics:
Can You Have Endometriosis Without Visible Symptoms?
